https://www.abbs.info
E-mail: [email protected]
ISSN
1672-9145
Acta Biochim Biophys Sin
2004, 36(9): 589–596
CN 31-1940/Q
Recombinant Bivalent Vaccine against Foot-and-Mouth Disease Virus
Serotype O/A Infection in Guinea Pig
Jian-Zhong YI, Ming-Qiu LIU, Cai-Zhu ZHU1, Qiang ZHANG,
Zu-Tian SHENG2, Qing-Yun DU2, Wei-Yao YAN, and Zhao-Xin ZHENG*
State Key Laboratory of Genetics Engineering, Life Science School,
Fudan University, Shanghai 200433, China;
1The
Veterinary Institute of Chinese Academy of Agricultural Sciences, Lanzhou
730046, China;
2The Virus Research
Institute of Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China
Abstract In this study, two DNA fragments encoding amino acid
(141–160)-(21–40)-(141–160) of the VP1 of FMDV (foot-and-mouth disease virus)
serotype O and (138–160)-(21–40)-(138–160) of the serotype A FMDV were
chemically synthesized. These two tandem-repeat fragments were ligated and
transfected into prokaryotic expression vector pTrcHis A to construct pTH-O-A.
The other vector called pTH-O-scIgG-A was constructed similarly only that the
two tandem-repeat DNA fragments were linked by the bovine-IgG heavy chain
coding sequence. Guinea pigs immunized with the two bivalent vaccines pTH-O-A
and pTH-O-scIgG-A showed both specific antibody activity and T cell proliferation
responses. FMDV challenge tests showed that 85% and 70% of guinea pigs
vaccinated twice with 200 mg of the fusion protein of pTH-O-A were protected from FMDV serotype
O and serotype A infection respectively. 70% and 57% of the guinea pigs
immunized with the fusion protein of pTH-O-scIgG-A were protected from FMDV
serotype O and serotype A infection respectively.
Key words foot-and-mouth disease; FMDV serotype O; FMDV serotype A; VP1
protein; bivalent vaccine; guinea pig
—————–
Received: May 11, 2004 Accepted: July 12, 2004
This study was supported by a grant from the National High
Technology Research and Development Program of China (No. 2001AA213071)
*Corresponding author: Tel, 86-21-65642504; Fax, 86-21-65642504;
E-mail, [email protected]